Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Drug, Biotech Stocks' Q2 Earnings on Aug 2: GILD, INCY & More
05:59pm, Monday, 01'st Aug 2022 Zacks Investment Research
Let's check out how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Aug 2.
Expert Ratings for Incyte
06:27pm, Thursday, 28'th Jul 2022 Benzinga
Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
1
2
2
0
Last 30D
0
0
1
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022
02:07pm, Thursday, 28'th Jul 2022 Benzinga
Upgrades
According to Argus Research, the prior rating for Huntington Bancshares Inc (NASDAQ:HBAN) was changed from Hold to Buy. In the second quarter, Huntington Bancshares showed an EPS of $0.36, c
Myovant Sciences (MYOV) Reports Q1 Loss, Tops Revenue Estimates
09:55pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
Myovant Sciences (MYOV) delivered earnings and revenue surprises of -69.23% and 8.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Incyte (INCY) to Report Q2 Earnings: What's in the Cards?
02:09pm, Tuesday, 26'th Jul 2022 Zacks Investment Research
Incyte's (INCY) top line is likely to have been driven by sales of its lead drug, Jakafi, in the second quarter.
10 Best Low-Volatility Stocks to Buy Now
02:01pm, Monday, 25'th Jul 2022
The stock market is suffering a turbulent 2022 so far – and with inflation still running at a 40-year high, the Federal Reserve locked in a significant rate-hiking cycle and midterm elections just m
2 Unstoppable Stocks Set to Keep Beating the Market in 2022
12:00pm, Saturday, 23'rd Jul 2022 The Motley Fool
Their drug prospects are helping them perform better than most stocks on the market this year.
2 Unstoppable Stocks Set to Keep Beating the Market in 2022
08:00am, Saturday, 23'rd Jul 2022
Their drug prospects are helping them perform better than most stocks on the market this year.
New Indication Approval For Incyte "To Usher New Growth Avenue"
05:03pm, Thursday, 21'st Jul 2022 Benzinga
JMP Securities reiterated its Market Outperform rating and increased the price target to $113 from $108 for Incyte Corporation (NASDAQ: INCY) based on multiple discounted earnings per share and re
Biotech Stock Roundup: APLS, NVAX Gain on Updates, INCYs Regulatory News & More
03:42pm, Wednesday, 20'th Jul 2022 Zacks Investment Research
'Regulatory and other updates from Apellis (APLS) and Novavax (NAVX) are a few key highlights from the biotech sector during the past week.
INCY vs. TECH: Which Stock Should Value Investors Buy Now?
01:11pm, Wednesday, 20'th Jul 2022
INCY vs. TECH: Which Stock Is the Better Value Option?
Incyte (INCY) Gets FDA Nod for Label Expansion of Opzelura
01:09pm, Tuesday, 19'th Jul 2022
Incyte (INCY) Opzelura cream 1.5% gets FDA approval for another indication - nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
Incyte gets FDA approval for a new vitiligo treatment
08:33am, Tuesday, 19'th Jul 2022
Incyte Corp. INCY, -1.46% said Monday that the Food and Drug Administration approved Opzelura as a topical repigmentation treatment for patients with nonsegmental vitiligo. Vitiligo is an autoimmune d
Incyte Corp. Should Move Higher (Technical Analysis)
02:50pm, Monday, 18'th Jul 2022
Incyte is outperforming the SP 500. Institutions are accumulating shares.
Incyte (INCY) Outperforms Industry YTD: What Lies Ahead?
12:22pm, Monday, 11'th Jul 2022
Incyte (INCY) outperforms the industry in the year so far as lead drug Jakafi maintains momentum. Pipeline progress has also been encouraging.
